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Objectives The purpose of this study was to determine the safety and efficacy of drug-eluting stents (DES) compared with
bare-metal stents (BMS) in older patients with chronic kidney disease (CKD).
Background DES may be associated with late death and myocardial infarction (MI) secondary to stent thrombosis. However,
data on outcomes in older patients with CKD are limited.
Methods We estimated the glomerular filtration rate (GFR) of 283,593 patients 65 years of age and older who underwent
stent implantation between 2004 and 2007. In propensity-matched cohorts grouped by GFR, the association
between DES and BMS and the risk of death, MI, revascularization, and major bleeding was examined.
Results A total of 121,446 patients (42.8%) had CKD (GFR 60 ml/min/1.73 m2). The 30-month mortality rate for pa-
tients on long-term dialysis was 52.0%. In propensity-matched pairs, placement of a DES compared with a BMS
in patients with normal renal function was associated with significant reductions in 30-month revascularization
(hazard ratio [HR]: 0.91; 95% confidence interval [CI]: 0.86 to 0.95), MI (HR: 0.77; 95% CI: 0.71 to 0.83), and
death (HR: 0.73; 95% CI: 0.69 to 0.77), but no difference in bleeding (HR: 0.89; 95% CI: 0.79 to 1.00). Lower MI
and mortality rates were also observed after DES compared with BMS implantation in all CKD subgroups with
the exception of MI in the long-term dialysis group. Decreased rates of revascularization did not extend to any
subgroup of patients with CKD.
Conclusions The safety of DES compared with BMS is observed in all patients regardless of renal function and is associated
with reduced rates of MI and death in some subsets of patients with CKD. (J Am Coll Cardiol 2011;58:
1859–69) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.06.056Open access under CC BY-NC-ND license.
Open access under CC BY-NC-ND license.Patients with chronic kidney disease (CKD) make up an
increasing percentage of the population undergoing percu-
taneous coronary intervention (PCI). This trend is largely a
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2011, accepted June 28, 2011.result of the growing number of patients with CKD,
estimated to exceed 19 million patients in the United States,
and the high prevalence of coronary artery disease in these
patients (1–3). However, their representation in randomized
trials of PCI therapies has been historically low because of
concerns about an increase in major in-hospital adverse
events, short- and long-term mortality, and lower proce-
dural success rates compared with patients with normal
renal function (4–6).
The drug-eluting stent (DES) has emerged as the stent of
choice in CKD patients in response to the high restenosis
rates of 13% to 35% seen with bare-metal stents (BMS) in
these patients (7–11). Although DES have been shown to
lower restenosis and revascularization rates in patients
enrolled in the randomized, controlled trials (RCTs) (12–14),
50% of DES are being placed in patient and anatomic
subsets that were not included in the large pivotal RCTs
(

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are safe and effective in older
patients with baseline CKD or
patients on long-term dialysis
has not been well studied, and
the recent concerns regarding in-
creased rates of late stent throm-
bosis in patients with CKD after
implantation of DES may offset
any potential benefit of decreased
revascularization (18–20).
The contemporary prevalence
of CKD in older patients under-
going PCI and the relative safety
and efficacy of DES compared
with those of BMS in this popu-
lation is unknown. Using data
from the linked American College
of Cardiology National Cardiovas-
cular Data Registry (NCDR) and
the Center for Medicare Services
national claims databases, we eval-
uated the outcomes of patients with increasing severity of
CKD including patients on dialysis and in these subgroups and
examined the association between DES and BMS and the
risks of death, myocardial infarction (MI), revascularization,
and major bleeding.
Methods
Study population. The NCDR CathPCI registry, co-
sponsored by the American College of Cardiology and
the Society for Cardiovascular Angiography and Inter-
ventions, was previously described (21,22). The registry
catalogs data on patient and hospital characteristics,
clinical presentation, treatments, and outcomes for PCI
procedures from more than 1,000 sites across the United
States. Data are entered into NCDR-certified software at
participating institutions and exported in a standard
format to the American College of Cardiology. There is
a standard dataset with written definitions, uniform data
entry and transmission requirements, and data quality
checks. The variables were prospectively defined by a
committee of the American College of Cardiology and
are available online (23).
This study included all Medicare-eligible patients 65
years of age and older undergoing PCI who were enrolled
in the CathPCI registry between January 1, 2004, and
December 31, 2007. Only patients enrolled using version
3.0 of the data forms (contains data on baseline creati-
nine) were included. Patients receiving more than 1 stent
type (i.e., both BMS and DES) or missing creatinine
values who were not on dialysis were excluded from the
analysis (Fig. 1). Patients were classified into 5 groups
according to the estimated glomerular filtration rate
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
CKD  chronic kidney
disease
DES  drug-eluting stent(s)
GFR  glomerular filtration
rate
HR  hazard ratio
IPW  inverse
probability–weighted
MI  myocardial infarction
NCDR  National
Cardiovascular Data
Registry
PCI  percutaneous
coronary intervention
RCT  randomized
controlled trial(GFR) using the 4-component MDRD (Modification ofDiet in Renal Disease study) equation incorporating age,
race, sex, and serum creatinine (24). The most recent
creatinine level before the day of the procedure was collected
on the case report forms. Patients were classified as having
normal renal function (GFR 60 ml/min/1.73 m2), mild
CKD (GFR 45 to 59 ml/min/1.73 m2), moderate CKD
GFR 30 to 44 ml/min/1.73 m2), severe CKD (GFR
30 ml/min/1.73 m2), and long-term dialysis (as indi-
cated by the case report form). The Duke University
Medical Center Institutional Review Board granted a
waiver of the informed consent and authorization for this
study.
Follow-up information. The CathPCI registry only covers
pre-hospital testing and in-hospital outcomes, so we used
the Medicare 100% inpatient fee-for-service claims file for
longitudinal patient follow-up. The CathPCI Registry-
CMS Claims Database linking rules were previously de-
scribed (25).
Clinical endpoints. We evaluated 4 primary clinical end-
points: death, MI, repeat revascularization, and follow-up
bleeding (26,27). Death was defined both during the index
PCI procedure (using American College of Cardiology
NCDR information) and post-discharge (using the Medicare
denominator file). Other clinical endpoints were defined
post-discharge only with the Medicare claims file as the
primary diagnosis for the hospital admission. The ICD-9
CM diagnosis codes used to identify events were MI
(410.X1) (26,27), major bleeding (430 through 432 [intra-
cerebral], 578.X [gastrointestinal tract], 719.1X [hemar-
throsis], 423.0 [hemopericardium], 599.7 [hematuria],
626.2, 626.6, 626.8, 627.0, 627.1 [vaginal], 786.3 [hemo-
ptysis], 784.7 [epistaxis], or 459.0 [hemorrhage not other-
wise specified]), and revascularizations (ICD-9 CM proce-
dure codes PCI: 36.00, 36.06, 36.07, 36.09; and coronary
artery bypass graft surgery: 36.10–19). Only revasculariza-
tions occurring after discharge from the index hospital stay
were included in the revascularization analysis.
Statistical analysis. Differences between groups were
compared using chi-square tests for categorical variables
and the Wilcoxon rank sum or Kruskal-Wallis test for
continuous variables. Event rates were calculated based
on Kaplan-Meier censoring estimates. Kaplan-Meier
event curves, stratified by CKD subgroup, were generated
and presented as cumulative incidence curves. To evalu-
ate the independent effect of CKD severity on outcomes,
we used a Cox proportional hazards model adjusted with
variables from the NCDR PCI mortality model (28,29).
Patients with normal renal function were used as the
referent group in all comparisons.
Propensity scores were developed for the receipt of
DES within each CKD subgroup such that the receipt of
a DES is the dependent variable conditioned on 102
observed covariates. We then matched each DES recip-
ient to a BMS control within each CKD subgroup by
using the estimated logit of the propensity score using a
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matched pairs in each subgroup, the reduction in the risk
of the outcome was compared between the DES and the
BMS groups with the use of a Cox regression model, with
stent type as the sole predictor. Analyses were performed
using SAS software version 9.0 (SAS Institute Inc., Cary,
North Carolina).
Sensitivity analyses. To further assess the robustness of
our findings, we performed a series of additional sensitivity
analyses. First, we also used inverse probability–weighted
Figure 1 Population Selection: Flow Diagram
ACC–NCDR  American College of Cardiology–National Cardiovascular Data Regist
CMS  Centers for Medicare and Medicaid Services; DES  drug-eluting stent(s);(IPW) estimators incorporating propensity scores to com- apare treatment groups. IPW estimators require fewer dis-
tributional assumptions and handle censored data (30).
djusted hazard ratios (HRs) were calculated according to
he IPW approach of Cole and Hernan (31). Second,
ecause propensity matching cannot be expected to balance
nmeasured confounders that are unrelated to the measured
onfounders, we estimated the magnitude of odds ratios
etween an unmeasured confounder and exposure that
ould invalidate our results (32). We varied the prevalence
f a potential confounder between 0.3 and 0.7 and assumed
S  bare-metal stent;
percutaneous coronary intervention.ry; BM
PCI strong association of the confounder to the outcome
e refer
ardial i
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ations between the unmeasured confounder and the expo-
sure so that the reported magnitudes are conservative.
Results
Severity of CKD and outcomes. Between January 1, 2004,
and December 31, 2007, 460,453 patients 65 years of age
and older underwent stent implantation, and 70.7% were
linked to Medicare longitudinal records. After exclusions
(Fig. 1), the study population included 283,593 patients
from 793 sites. Comparison of NCDR patients who did and
did not match to Medicare records revealed nonmatch
patients (Online Table 1) to be slightly younger (age 73.6
HRs for Death, MI, Revascularization, and Bleeding According to CTable 1 HRs for Death, MI, Revascularization, and Bleeding Ac
Outcome
GFR >60 ml/min/1.73 m2
Normal
(n  162,417)
GFR 45–59 ml/min/1.73 m
Mild CKD
(n  73,751)
Death* 10.5 13.8
Unadjusted HR 1.0† 1.31 (1.27–1.35)
Adjusted HR‡ 1.11 (1.08–1.15)
MI* 5.6 6.6
Unadjusted HR 1.0† 1.21 (1.15–1.26)
Adjusted HR‡ 1.06 (1.01–1.11)
Revascularization* 18.2 18.4
Unadjusted HR 1.0† 1.02 (1.00–1.04)
Adjusted HR‡ 1.02 (1.00–1.05)
Major bleeding* 3.0 3.7
Unadjusted HR 1.0† 1.21 (1.14–1.29)
Adjusted HR‡ 1.09 (1.02–1.16)
Values are % or HR (95% confidence interval). *Kaplan-Meier event rate. †This group served as th
CKD  chronic kidney disease; GFR  glomerular filtration rate; HR  hazard ratio; MI  myoc
Figure 2 Prevalence of CKD by Age
CKD  chronic kidney disease; GFR  glomerular filtration rate.years vs. 74.7 years) and more likely to be men (61.8% vs.
58.0%) and to live in the Western United States (24.3% vs.
14.3%).
There were 162,147 patients (57.2%) with normal
renal function, 73,751 (26.0%) with mild CKD, 34,004
(12.0%) with moderate CKD, 8,509 (3.0%) with severe
CKD, and 5,182 (1.8%) on long-term dialysis who
underwent PCIs. The prevalence of mild, moderate, and
severe CKD patients increased with increasing age,
whereas the prevalence of dialysis patients decreased
(Fig. 2). The proportions of patients with coexisting
comorbidities at baseline increased with increasing sever-
ity of CKD (Online Table 2).
ubgroup at 30 Monthsng to CKD Subgroup at 30 Months
FR 30–44 ml/min/1.73 m2
Moderate CKD
(n  34,004)
GFR <30 ml/min/1.73 m2
Severe CKD
(n  8,509)
Dialysis
(n  5,182)
22.0 32.7 51.9
2.29 (2.22–2.37) 3.73 (3.55–3.91) 6.63 (6.31–6.97)
1.45 (1.40–1.51) 1.87 (1.76–1.98) 3.55 (3.36–3.74)
9.0 13.7 19.5
1.61 (1.53–1.71) 2.31 (2.12–2.52) 3.75 (3.43–4.11)
1.14 (1.07–1.20) 1.34 (1.21–1.49) 2.11 (1.91–2.31)
18.1 20.7 23.9
0.99 (0.96–1.03) 1.02 (0.96–1.09) 1.22 (1.13–1.32)
0.97 (0.94–1.01) 0.97 (0.90–1.04) 1.13 (1.04–1.23)
4.9 6.3 9.6
1.73 (1.61–1.86) 2.32 (2.06–2.61) 3.20 (2.79–3.66)
1.31 (1.21–1.42) 1.59 (1.38–1.82) 2.27 (1.97–2.60)
ence group. ‡Covariates used are listed in the Online Appendix.
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October 25, 2011:1859–69 Drug-Eluting Stents and Chronic Kidney DiseaseFigure 3 shows the Kaplan-Meier cumulative incidence
curves stratified by CKD severity. Increasing severity of
CKD was associated with increasing mortality rates.
Mortality rates were extremely high in patients with
severe CKD, with 30-month mortality rates of 32.7%
(95% confidence interval [CI]: 31.2 to 34.1) and peaked
in patients on long-term dialysis at 51.9% (95% CI: 49.8
to 54.0). Increasing severity of CKD was also associated
with increasing rates of MI, revascularization, and bleed-
ing (Table 1).
Using patients with normal renal function (GFR 60
ml/min/1.73 m2) as the reference group, there was a graded
ncrease in the association of CKD severity with adjusted
ates of death, MI, and major bleeding (Table 1). Dialysis
atients had the highest adjusted rates of death (adjusted
R: 3.55; 95% CI: 3.36 to 3.74), MI (adjusted HR: 2.11;
5% CI: 1.91 to 2.31), and major bleeding (adjusted HR:
.27; 95% CI: 1.97 to 2.60). Significant increases in revas-
ularization were only seen in the dialysis group (adjusted
R: 1.13; 95% CI: 1.04 to 1.23).
ES cohort compared with BMS cohort. The baseline
haracteristics of the 283,593 patients who underwent
CIs grouped by both CKD severity and type of stent
eceived are shown in Online Table 2. Overall, 65,063
Figure 3 Stratified Cumulative Incidence Curves by Severity of
Cumulative incidence for death (A), myocardial infarction (MI) (B), revascularizatioatients (22.9%) received a BMS. In the entire studyopulation, BMS patients were significantly older with a
igher prevalence of smoking and history of congestive
eart failure, peripheral arterial disease, stroke, and
hronic lung disease compared with patients treated with
ES. In all subgroups examined, patients receiving DES
ere more likely to have had a previous PCI and to
resent for an elective PCI.
ES propensity cohort compared with BMS propensity
ohort. After propensity-score matching, there were
21,942 matched pairs overall (60,971 patients who received
ES and 60,971 who received BMS). The patient charac-
eristics and clinical factors of the propensity-matched
opulation are shown in Table 2. The standardized differ-
nces between the 2 groups within each CKD stratum were
ess than 10%, indicating good balance of the covariates.
ompared with BMS, DES treatment was associated with
ower 30-month death rates in patients with normal renal
unction (12.2% vs. 14.7%, p  0.001), mild CKD (15.1%
s. 18.6%, p  0.001), moderate CKD (24.1% vs. 26.6%,
 0.001), and severe CKD (33.7% vs. 33.7%, p  0.04)
and patients on long-term dialysis (48.9% vs. 56.4%, p 
0.001) (Table 3, Fig. 4).
Overall, MI rates at 30 months were lower in the DES
compared with the BMS patients (7.2% vs. 8.2%, p 
and major bleeding (D). CKD  chronic kidney disease.CKD
n (C),0.001). The use of DES compared with BMS was also
a
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Drug-Eluting Stents and Chronic Kidney Disease October 25, 2011:1859–69associated with lower adjusted 30-month MI rates in
patients with normal renal function or mild, moderate, or
severe CKD. This pattern was not observed in patients on
long-term dialysis. Revascularization rates at 30 months
were slightly lower in the DES compared with BMS
patients (18.1% vs. 18.4%, p 0.001). There appeared to be
differential reduction in revascularization rates for DES
ompared with BMS (interaction p 0.01) in patients with
ormal renal function only, whereas patients with mild,
oderate, or severe CKD and patients on dialysis did not
how significant differences. Major bleeding rates at 30
onths were slightly lower in the DES compared with the
MS subgroup (3.9% vs. 4.1%, p  0.04). After adjust-
ent, DES use in the severe CKD subgroup was associated
ith significant reductions in the incidence of 30-month
ates of hospitalization for bleeding, whereas no differences
ere seen in the other groups.
ensitivity analyses. Comparison of DES and BMS using
PW adjustment yielded findings consistent with the pro-
ensity analysis (Fig. 4). Sensitivity analysis of residual
onfounding indicated that an unmeasured confounder
ould need to be associated with a greater than 9-fold
ncrease in the odds of selecting a DES with a large
rotective effect on mortality (HR: 0.50) to eliminate the
Demographics and Baseline Characteristics of Propensity MatchedTable 2 Demographics and Baseline Characteristics of Propens
GFR >60 ml/min/1.73 m2
Normal
DES
(n  33,648)
BMS
(n  33,648) p Value
Age, yrs 74.4 6.4 74.5 6.6 0.688
Male 22,205 (66.0) 22,198 (66.0) 0.955
Current smoking 5,234 (15.6) 5,267 (15.7) 0.726
CHF (previous or current) 24,128 (71.7) 24,211 (72.0) 0.477
HTN 26,110 (77.6) 26,126 (77.6) 0.882
Renal failure
No dialysis 370 (1.1) 357 (1.1) 0.628
Dialysis
DM
Non–insulin-dependent 7,374 (21.9) 7,240 (21.5) 0.210
Insulin-dependent 2,232 (6.6) 2,226 (6.6) 0.926
PVD 4,847 (14.4) 4,806 (14.3) 0.652
Stroke 5,069 (15.1) 5,028 (14.9) 0.658
Chronic lung disease 6,801 (20.2) 6,741 (20.0) 0.564
Previous PCI 7,831 (23.3) 7,789 (23.1) 0.701
Previous CABG 7,813 (23.2) 7,684 (22.8) 0.238
Previous MI 8,155 (24.2) 8,133 (24.2) 0.843
Indication
No symptoms, no angina 5,064 (15.1) 4,993 (14.8) 0.441
Atypical chest pain 2,279 (6.8) 2,297 (6.8) 0.784
Stable angina 4,749 (14.1) 4,725 (14.0) 0.788
Unstable angina 10,510 (31.2) 10,415 (31.0) 0.426
NSTEMI 6,209 (18.5) 6,256 (18.6) 0.644
STEMI 4,835 (14.4) 4,962 (14.7) 0.166
Multivessel PCI 3,693 (11.0) 3,733 (11.1) 0.623
Off-label PCI 18,147 (78.8)
Values are mean  SD or n (%).
BMS bare-metal stent; CABG coronary artery bypass graft; CHFcongestive heart failure; DE
myocardial infarction; PCI  percutaneous coronary artery intervention; PVD peripheral vascular disignificant associations of our findings.Discussion
In the largest observational real-world study evaluating
older patients undergoing PCI, we found that pre-
existing kidney disease was a common condition, preva-
lent in more than one-third of older patients and is
associated with increased risk of death, MI, revascular-
ization, and major bleeding after PCI. Our study dem-
onstrates a very high mortality in patients with severe
CKD and patients on long-term dialysis, with nearly 1 in
3 (32.7%) and more than one-half (52.0%), respectively,
dying within 3 years. Despite these high adverse event
rates, we observed a significant reduction in risk-adjusted
mortality, MI, and revascularization associated with the
use of DES compared with BMS in patients with normal
renal function and most subgroups of patients with CKD,
but not patients on long-term dialysis. Importantly, we
did not detect a significant safety hazard with the use of
DES compared with BMS across the spectrum of high-
risk elderly patients with CKD.
The association between CKD and cardiovascular
outcomes has been the focus of many studies over the past
decade. Most of the data have been consistent, with our
study showing worsened short- and long-term clinical
outcomes including death in a dose-dependent fashion
ulationatched Population
GFR 45–59 ml/min/1.73 m2
Mild CKD
ndardized
fference
DES
(n  15,977)
BMS
(n  15,977) p Value
Standardized
Difference
0.6 76.2 6.6 76.1 6.8 0.613 0.2
0.0 8,290 (51.9) 8,295 (51.9) 0.955 0.1
0.3 2,006 (12.6) 1,977 (12.4) 0.623 0.5
0.5 12,028 (75.3) 12,033 (75.3) 0.948 0.1
0.1 13,317 (83.4) 13,291 (83.2) 0.697 0.4
0.4 707 (4.4) 721 (4.5) 0.705 0.4
1.0 3,649 (22.8) 3,693 (23.1) 0.558 0.7
0.1 1,554 (9.7) 1,543 (9.7) 0.835 0.2
0.3 2,651 (16.6) 2,676 (16.7) 0.707 0.4
0.3 2,868 (18.0) 2,879 (18.0) 0.873 0.2
0.4 3,282 (20.5) 3,288 (20.6) 0.934 0.1
0.3 3,902 (24.4) 3,901 (24.4) 0.990 0.0
0.9 4,061 (25.4) 4,008 (25.1) 0.495 0.8
0.2 4,262 (26.7) 4,247 (26.6) 0.849 0.2
0.6 2,292 (14.3) 2,268 (14.2) 0.698 0.4
0.2 1,043 (6.5) 1,018 (6.4) 0.567 0.6
0.2 2,131 (13.3) 2,172 (13.6) 0.504 0.7
0.6 4,795 (30.0) 4,792 (30.0) 0.965 0.0
0.4 3,158 (19.8) 3,108 (19.5) 0.478 0.8
1.1 2,556 (16.0) 2,619 (16.4) 0.341 1.1
0.4 1,860 (11.6) 1,845 (11.5) 0.793 0.3
8,376 (79.7)
g-eluting stent; DM diabetesmellitus; HTN hypertension; NSTEMI non–ST-segment elevation
TEMI  ST-segment elevation myocardial infarction; other abbreviations as in Table 1.Popity M
Sta
Diwith increasing serum creatinine during and after PCI
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patients and provides important insights into clinical
outcomes in this poorly studied population. Compared
with patients with normal renal function, those on
Table 2
GFR 30–44 ml/min/1.73 m2
Moderate CKD
GFR <30 m
Seve
DES
(n  7,944)
BMS
(n  7,944) p Value
Standardized
Difference
DES
(n  2,066)
BMS
(n  2,066
78.1 6.7 78.0 6.9 0.392 1.3 77.9 6.8 77.8 6.
3,706 (46.7) 3,708 (46.7) 0.975 0.1 819 (39.6) 819 (39.
786 (9.9) 803 (10.1) 0.653 0.7 206 (10.0) 224 (10.
6,289 (79.2) 6,289 (79.2) 1.000 0.0 1,718 (83.2) 1,716 (83.
6,935 (87.3) 6,928 (87.2) 0.868 0.3 1,861 (90.1) 1,859 (90.
1,453 (18.3) 1,445 (18.2) 0.869 0.3 1,157 (56.0) 1,159 (56.
2,072 (26.1) 2,034 (25.6) 0.491 1.1 519 (25.1) 541 (26.
1,161 (14.6) 1,176 (14.8) 0.737 0.5 468 (22.7) 460 (22.
1,754 (22.1) 1,714 (21.6) 0.442 1.2 543 (26.3) 541 (26.
1,831 (23.0) 1,799 (22.6) 0.545 1.0 518 (25.1) 514 (24.
1,831 (23.0) 1,790 (22.5) 0.438 1.2 526 (25.5) 501 (24.
1,982 (24.9) 2,003 (25.2) 0.701 0.6 476 (23.0) 439 (21.
2,287 (28.8) 2,211 (27.8) 0.181 2.1 512 (24.8) 507 (24.
2,437 (30.7) 2,397 (30.2) 0.490 1.1 635 (30.7) 629 (30.
1,156 (14.6) 1,109 (14.0) 0.286 1.7 305 (14.8) 286 (13.
461 (5.8) 476 (6.0) 0.613 0.8 85 (4.1) 83 (4.0
937 (11.8) 930 (11.7) 0.863 0.3 196 (9.5) 204 (9.9
2,284 (28.8) 2,290 (28.8) 0.916 0.2 562 (27.2) 555 (26.
1,812 (22.8) 1,832 (23.1) 0.706 0.6 535 (25.9) 564 (27.
1,294 (16.3) 1,307 (16.5) 0.780 0.4 383 (18.5) 374 (18.
982 (12.4) 1,009 (12.7) 0.518 1.0 271 (13.1) 280 (13.
4,206 (81.9) 1,000 (79.1)
Death, MI, Revascularization, and Bleeding Rates at 30 MonthsTable 3 Death, MI, Revascularization, and Bleeding Rates at 3
Overall
(N  127,308)
GFR >60 ml/min/1.73 m2
Normal
(n  72,174)
GFR 45–59 ml/m
Mild CK
(n  31,
Death
DES 16.1 11.9 15.0
BMS 18.8 14.6 18.6
p value 0.001 0.001 0.00
Any MI
DES 6.9 5.7 6.5
BMS 8.1 7.0 7.3
p value 0.001 0.001 0.00
Revascularization
DES 18.0 17.8 18.1
BMS 18.5 18.7 17.5
p value 0.001 0.001 0.10
Bleeding
DES 4.2 3.5 4.4
BMS 4.1 3.4 4.0
p value 0.462 0.162 0.25KM  Kaplan-Meier; other abbreviations as in Tables 1 and 2.dialysis had a 3.6-fold increased risk of death, a 2.1-fold
increased risk of MI, and a 2.3-fold increased risk of
major bleeding at 30-month follow-up. Long-term dial-
ysis patients also had higher rates of repeat revascular-
1.73 m2
Dialysis
Value
Standardized
Difference
DES
(n  1,336)
BMS
(n  1,336) p Value
Standardized
Difference
0.638 1.2 74.0 6.3 74.1 6.4 0.782 1.9
1.000 0.0 775 (58.0) 784 (58.7) 0.724 1.4
0.359 2.9 131 (9.8) 131 (9.8) 1.000 0.0
0.934 0.3 1,065 (79.7) 1,075 (80.5) 0.628 1.9
0.917 0.3 1,234 (92.4) 1,232 (92.2) 0.885 0.6
0.950 0.2
1,336 (100.0) 1,336 (100.0) .
0.433 2.4 357 (26.7) 357 (26.7) 1.000 0.0
0.766 0.9 490 (36.7) 487 (36.5) 0.904 0.5
0.944 0.2 518 (38.8) 502 (37.6) 0.524 2.5
0.886 0.4 352 (26.3) 361 (27.0) 0.694 1.5
0.368 2.8 379 (28.4) 368 (27.5) 0.635 1.8
0.166 4.3 338 (25.3) 331 (24.8) 0.755 1.2
0.857 0.6 393 (29.4) 383 (28.7) 0.670 1.6
0.839 0.6 451 (33.8) 452 (33.8) 0.967 0.2
0.399 2.6 271 (20.3) 278 (20.8) 0.745 1.3
0.875 0.5 105 (7.9) 102 (7.6) 0.824 0.9
0.674 1.3 131 (9.8) 135 (10.1) 0.801 1.0
0.806 0.8 402 (30.1) 389 (29.1) 0.573 2.2
0.307 3.2 329 (24.6) 334 (25.0) 0.831 0.8
0.717 1.1 97 (7.3) 98 (7.3) 0.945 0.3
0.680 1.3 192 (14.4) 197 (14.7) 0.784 1.1
772 (81.3)
nths
KM Rate, %
73 m2 GFR 30–44 ml/min/1.73 m2
Moderate CKD
(n  16,148)
GFR <30 ml/min/1.73 m2
Severe CKD
(n  4,266)
Dialysis
(n  2,730)
24.7 34.6 53.2
26.8 34.1 55.9
0.002 0.125 0.066
9.6 15.0 22.9
11.9 12.8 21.2
0.007 0.026 0.463
17.6 19.4 23.9
18.3 20.1 23.8
0.909 0.431 0.959
5.9 4.7 10.7
5.6 9.5 7.5
0.874 0.002 0.261l/min/
re CKD
) p
9
6)
8)
1)
0)
1)
2)
3)
2)
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2)
2)
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8)
)
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moderate, or severe CKD patients.
Evidence of DES safety and efficacy has primarily
come from both RCTs and large-scale observational
registry studies (34,36 –39). Kirtane et al. (40) high-
lighted the differences in RCTs compared with observa-
tional studies in a comprehensive meta-analysis showing
that in RCTs, DES (compared with BMS) were associ-
ated with no detectable differences in overall mortality or
MI, with a significant 55% reduction in target vessel
revascularization. In contrast, observational studies have
consistently shown that DES use was associated with
significant reductions in mortality, MI, and target vessel
Figure 4 Safety and Efficacy Outcomes at 30-Month Follow-Up
Shown are the propensity-matched and inverse probability–weighted (IPW) hazard r
Death (A), myocardial infarction (B), revascularization (C), major bleeding (D). Abrevascularization compared with BMS. The differences inthe results of RCTs and observational studies highlight
the advantages and disadvantages of different study de-
signs. Where observational studies falter with regard to
unmeasured confounders, they have strength in the num-
ber of patients enrolled, the power to detect differences in
low-rate safety endpoints, and excellent external gener-
alizability. RCTs eliminate bias through randomization
but apply to restricted trial populations with inadequate
statistical power to detect important differences in low-
frequency outcomes such as mortality. Therefore, the
findings from RCTs and observational studies should be
viewed as complementary.
Our results suggest that the use of DES in patients 65
(HRs) and the 95% confidence intervals stratified by baseline kidney function.
ions as in Figures 1 and 2.atios
breviatyears of age and older with normal renal function and
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October 25, 2011:1859–69 Drug-Eluting Stents and Chronic Kidney Diseasemild, moderate, or severe CKD as well as dialysis patients
is associated with a lower absolute and adjusted mortality
than patients who receive BMS. Similar benefits are also
seen in the 30-month MI endpoint except that an
associated decrease in MI is not seen in the long-term
dialysis subgroup. These data support the use of DES in
patients with CKD, and there does not appear to be any
signal of harm in any CKD subgroup including dialysis
patients. Although a mortality benefit has not been
demonstrated among RCTs, this limitation could reflect
limited follow-up, the enrollment of only low-risk pa-
tients with low event rates, or a relatively small number of
patients. Alternatively, our mortality data could represent
residual unmeasured confounding by indication where
Figure 4 ContinuedBMS placement is a surrogate for sicker patients thatpersists despite the adjustment of many variables and
multiple sensitivity analyses that support our primary
findings.
Because our follow-up was linked to the Medicare
administrative data files, it is not possible to determine
target vessel revascularization or stent thrombosis
through ICD-9 coding. However, we were able to detect
general repeat revascularization procedures (PCI or cor-
onary artery bypass graft surgery) and found that DES
use was associated with decreased revascularization in
patients with normal renal function but not in patients
with CKD. Small studies have shown an association
between DES and lower restenosis and total lesion
revascularization rates in patients with mildly impaired
renal function, whereas others have not shown any
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CKD (19,41– 43).
Study limitations. There are several important consider-
ations when interpreting the results of this study. First,
patients and hospitals participating in the NCDR may
not be representative of all U.S. practice and represent
only patients older than the age of 65. However, the
CathPCI registry represents more than 1,000 hospitals
across the United States and thus captures a significant
portion of PCIs nationally. Second, our linked dataset
does not have data on medication during the longitudinal
follow-up period. Therefore, we could not directly assess
the influence of dual-antiplatelet therapy on our findings,
which is likely a critical effect modifier of DES outcomes.
Third, as in all observational studies, unmeasured con-
founders that could influence the receipt of a BMS
instead of a DES must be considered. However, multiple
sensitivity analyses performed in our study and the
sentinel NCDR-linked Medicare cohort looking at the
overall DES cohort compared with BMS cohort yielded
similar results (24). Fourth, although mortality after
stenting was very high in severe CKD and dialysis, it is
unclear what the survival would have been without
revascularization. The lack of an appropriate comparator
arm (medically treated coronary artery disease patients
only) makes inferences about the effectiveness of PCI
versus medical therapy incomplete.
Conclusions
In a large national cohort study of Medicare beneficiaries
undergoing PCIs, we found that 40% of older patients
ndergoing PCIs have CKD. A strong, independent
raded association between increasing severity of CKD
nd increasing cardiovascular events was observed. Pa-
ients with normal renal function and most subgroups of
KD who received a DES had significantly lower mor-
ality rates throughout 30 months of follow-up. The
enefits of DES with regard to MI, revascularization, and
ajor bleeding were present in most, but not all, sub-
roups. In the absence of a definitive large RCT, this is
he largest registry study to date that suggests that DES
ppear to be safe in older patients with varying levels of
KD undergoing PCIs.
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